DARE Dare Bioscience, Inc. Quick Ratio

Dare Bioscience, Inc. (DARE) dominates the gynecology segment thanks to its exclusive treatment for bacterial vaginosis. The company is implementing unconventional drug delivery methods, creating unique products for contraception and the therapy of sexual dysfunctions. A balanced development portfolio across various trial stages mitigates the risks of narrow specialization. The price action, which currently stands at 1.03, is illustrated in the chart below.

To protect capital, an investor assesses the ability of Dare Bioscience, Inc. (DARE) to meet short-term obligations using its most liquid assets. Since Dare Bioscience, Inc. (DARE) focuses on intellectual property licensing rather than product sales, this liquidity metric—excluding non-liquid assets—accurately measures the reserve of cash and accounts receivable, removing inventory from the solvency analysis.